Insider Selling: Enliven Therapeutics, Inc. (NASDAQ:ELVN) Insider Sells $150,225.00 in Stock

Enliven Therapeutics, Inc. (NASDAQ:ELVN) insider Joseph P. Lyssikatos sold 7,500 shares of the stock in a transaction dated Tuesday, June 3rd. The stock was sold at an average price of $20.03, for a total value of $150,225.00. Following the sale, the insider now owns 977,688 shares of the company’s stock, valued at $19,583,090.64. This represents a 0.76% decrease in their position. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Enliven Therapeutics Trading Down 2.9%

Shares of Enliven Therapeutics stock opened at $20.74 on Friday. The stock has a 50 day moving average of $18.08 and a 200 day moving average of $20.82. Enliven Therapeutics, Inc. has a 12 month low of $13.30 and a 12 month high of $30.03. The firm has a market cap of $1.02 billion, a PE ratio of -10.92 and a beta of 1.07.

Enliven Therapeutics (NASDAQ:ELVN) last announced its quarterly earnings results on Wednesday, May 14th. The company reported ($0.57) EPS for the quarter, missing analysts’ consensus estimates of ($0.51) by ($0.06). As a group, equities research analysts forecast that Enliven Therapeutics, Inc. will post -1.95 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ELVN. HC Wainwright increased their target price on Enliven Therapeutics from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Thursday, May 15th. Jones Trading cut their target price on Enliven Therapeutics from $36.00 to $27.00 and set a “buy” rating for the company in a research report on Friday, May 16th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock presently has an average rating of “Buy” and a consensus price target of $37.25.

Hedge Funds Weigh In On Enliven Therapeutics

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in ELVN. Polar Capital Holdings Plc boosted its stake in Enliven Therapeutics by 267.6% during the fourth quarter. Polar Capital Holdings Plc now owns 2,389,668 shares of the company’s stock valued at $53,768,000 after buying an additional 1,739,668 shares during the last quarter. Boxer Capital Management LLC bought a new stake in shares of Enliven Therapeutics in the 4th quarter valued at approximately $15,106,000. Janus Henderson Group PLC lifted its stake in shares of Enliven Therapeutics by 27.9% in the 4th quarter. Janus Henderson Group PLC now owns 1,331,877 shares of the company’s stock valued at $30,001,000 after purchasing an additional 290,153 shares during the last quarter. FMR LLC lifted its stake in shares of Enliven Therapeutics by 3.2% in the 4th quarter. FMR LLC now owns 6,495,871 shares of the company’s stock valued at $146,157,000 after purchasing an additional 199,692 shares during the last quarter. Finally, Pictet Asset Management Holding SA lifted its stake in shares of Enliven Therapeutics by 16.3% in the 4th quarter. Pictet Asset Management Holding SA now owns 972,293 shares of the company’s stock valued at $21,877,000 after purchasing an additional 135,969 shares during the last quarter. 95.08% of the stock is owned by institutional investors.

About Enliven Therapeutics

Enliven Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company’s lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations.